RUA revenue rose 490.6% but the business remains deeply cash-negative

The loss before tax narrowed 74.8% to NZD 3.5m from NZD 13.7m, though the FY24 comparison was heavily distorted by a goodwill impairment of approximately NZD 8.3m and other one-off impairments, meaning the underlying operating improvement is real but smaller than the headline figure implies.

Cash fell sharply to NZD 0.2m from NZD 0.9m at the prior year-end. Operating cash outflows were NZD 2.8m, improved from NZD 3.7m in FY24, but the business remains entirely cash-negative and is dependent on external funding to operate. Total liabilities nearly doubled to NZD 1.9m, and new borrowings of NZD 0.7m were drawn during the year.

The second half was more productive: implied H2 revenue was NZD 1.2m versus NZD 0.7m in H1, and implied H2 operating cash outflows narrowed to NZD 0.8m from NZD 1.9m in H1.

With only NZD 0.2m in cash at year-end, NZD 0.7m in borrowings drawn, and operating outflows of NZD 2.8m for the year, the business has minimal financial headroom. Even at the improved H2 burn rate, the available cash covers only weeks of operations without additional funding.

The FY24 loss comparison is not clean. The FY24 PBT of NZD 13.7m included a goodwill impairment of approximately NZD 8.3m and other non-cash write-downs. Stripping these out, the underlying improvement in operating performance is meaningful — revenue is building from near-zero — but the 74.8% loss reduction overstates the pace of operating improvement. Investors should focus on the absolute cash burn trajectory rather than the reported loss-narrowing percentage.

Revenue mix is improving but concentration risk is unresolved. Revenue from customers rose to 79.5% of total revenue (NZD 1.5m) from 26.7% in FY24, which is directionally positive for a medicinal cannabis business transitioning from R&D to commercial stage. The H2 revenue acceleration suggests the distribution strategy is gaining traction, but customer concentration, geographic mix, and gross margin are not disclosed, making the quality of this revenue difficult to assess.

The release notes strong momentum expected to continue into FY26 and references expanded markets including Germany and the UK. The H2 revenue run-rate of NZD 1.2m, if sustained, would imply an annualised revenue approaching NZD 2.4m, though that would still fall well short of the level needed to approach cash breakeven given the current cost base.

The central uncertainty is whether revenue growth can outpace cash consumption quickly enough to avoid further dilutive capital raises. The trajectory is improving, but the gap between revenue and cash breakeven remains large relative to available liquidity.

The loss improvement is partially genuine and partially base-effect. Removing the FY24 impairment distortion, the underlying operating loss narrowed by a more modest but still positive amount, driven by real commercial revenue rather than cost cuts or balance-sheet assistance. The H2 operating cash outflow of NZD 0.8m is the most encouraging single data point in this result — it suggests the business is approaching a lower steady-state burn rate as revenues scale.

However, the result is not high quality in the conventional sense. The company remains pre-profit, cash is near-exhausted, and equity has declined to NZD 4.9m from NZD 6.8m. Trade receivables grew to NZD 0.2m from NZD 0.03m, and receivable days extended to 41.1 days from 29.7 days, which is consistent with growth-stage scaling but means working capital is absorbing some of the revenue increase. Capital intensity is negligible at 0.2% of revenue, which is appropriate for a genetics-and-distribution model, but that also means there is limited fixed-cost leverage to drive future margin improvement.

This briefing cannot assess pipeline optionality, regulatory approval timelines, or the probability of achieving cash-flow breakeven without disclosed cost-structure detail and forward revenue commitments.